Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 3(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00327561Phase 3Completed

Effect of Intensive Periodontal Therapy on Vascular Function

Role: collaborator

NCT00123227Phase 3Unknown

Rosiglitazone Plaque Study

Role: collaborator

NCT00103753Phase 4Unknown

Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major

Role: collaborator

All 3 trials loaded